<DOC>
	<DOCNO>NCT01159756</DOCNO>
	<brief_summary>This study multi-site , unmasked phase IV study . Travacom ( R ) combination topical ocular agent , contain travoprost timolol , low intraocular pressure ( IOP ) complementary mechanisms action . The safety efficacy travoprost timolol establish single adjunctive therapy well-controlled clinical study thousand patient diagnose open angle glaucoma ( OAG ) ocular hypertension . The objective study ass safety efficacy change Travacom prior pharmacotherapy uncontrolled patient open-angled glaucoma ocular hypertension across India .</brief_summary>
	<brief_title>To Assess Safety Efficacy Travacom Patients With Uncontrolled Intraocular Pressure</brief_title>
	<detailed_description />
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Must clinical diagnosis ocular hypertension , primary openangle pigment dispersion glaucoma eye . Must willing discontinue use ocular hypotensive medication prior receive study medication entire course study . Must able follow instruction willing able attend study visit . A known medical history allergy , hypersensitivity poor tolerance component Travacom deem clinically significant opinion Principle Investigator . Any abnormality prevent reliable applanation tonometer either eye . Corneal dystrophy . Any opacity subject uncooperativeness restricts adequate examination ocular fundus anterior chamber either eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Travacom</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Travoprost</keyword>
	<keyword>Timolol</keyword>
</DOC>